Company intelligence / Profile preview
Almac Discovery
Craigavon, UKalmacgroup.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Almac Discovery has multiple programs in development, including a WEE1 inhibitor that has advanced into clinical studies for advanced solid tumors. Their ALM201 compound, a microtubule binding agent for solid tumors, entered Phase I trials.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small molecules (NCEs)Novel Protein TherapeuticsProtein Drug Conjugates (PDCs)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
HitGenpharmaceutical partners for development
Beyond the preview
Go deeper on Almac Discovery.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Almac Discovery.